AD-301

AD-301 is an investigational oral drug candidate being developed by Addpharma, a subsidiary of Yuhan Corporation, for the treatment of non-alcoholic steatohepatitis (NASH), recently renamed metabolic dysfunction-associated steatohepatitis (MASH). While Addpharma's portfolio primarily consists of incrementally modified drugs (IMDs), AD-301 is categorized as a "New Drug" (신약) within their development pipeline, suggesting it is a new chemical entity. The compound entered Phase 1 clinical trials in South Korea in early 2022 to evaluate its safety, tolerability, and pharmacokinetic profile in healthy volunteers. As of early 2024, the specific molecular target and mechanism of action for AD-301 remain proprietary and have not been publicly disclosed by the developer.